Community Bank & Trust Waco Texas boosted its position in shares of Becton Dickinson and Co (NYSE:BDX) by 132.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,643 shares of the medical instruments supplier’s stock after purchasing an additional 1,506 shares during the period. Community Bank & Trust Waco Texas’ holdings in Becton Dickinson and were worth $690,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Ascension Asset Management LLC grew its holdings in Becton Dickinson and by 4.2% during the 2nd quarter. Ascension Asset Management LLC now owns 4,970 shares of the medical instruments supplier’s stock worth $1,191,000 after acquiring an additional 200 shares in the last quarter. Bfsg LLC grew its holdings in Becton Dickinson and by 1.9% during the 2nd quarter. Bfsg LLC now owns 10,515 shares of the medical instruments supplier’s stock worth $2,519,000 after acquiring an additional 201 shares in the last quarter. Toth Financial Advisory Corp grew its holdings in Becton Dickinson and by 0.8% during the 2nd quarter. Toth Financial Advisory Corp now owns 24,989 shares of the medical instruments supplier’s stock worth $5,986,000 after acquiring an additional 203 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in Becton Dickinson and by 0.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 50,849 shares of the medical instruments supplier’s stock worth $12,181,000 after acquiring an additional 204 shares in the last quarter. Finally, Spearhead Capital Advisors LLC grew its holdings in Becton Dickinson and by 1.4% during the 3rd quarter. Spearhead Capital Advisors LLC now owns 15,525 shares of the medical instruments supplier’s stock worth $3,887,000 after acquiring an additional 218 shares in the last quarter. 92.51% of the stock is owned by institutional investors and hedge funds.

Several research analysts have weighed in on BDX shares. JPMorgan Chase & Co. raised shares of Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price objective for the company in a report on Thursday, June 21st. ValuEngine raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating in a report on Tuesday, June 26th. KeyCorp restated a “buy” rating and issued a $264.00 price target on shares of Becton Dickinson and in a research report on Friday, August 3rd. Royal Bank of Canada restated a “hold” rating and issued a $248.00 price target on shares of Becton Dickinson and in a research report on Friday, August 3rd. Finally, Citigroup raised their price target on shares of Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $253.79.

Becton Dickinson and stock opened at $242.62 on Friday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23. Becton Dickinson and Co has a 1 year low of $197.44 and a 1 year high of $265.87. The stock has a market capitalization of $69.83 billion, a PE ratio of 25.59, a price-to-earnings-growth ratio of 1.78 and a beta of 1.11.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.86 by $0.05. Becton Dickinson and had a net margin of 4.73% and a return on equity of 14.16%. The company had revenue of $4.28 billion for the quarter, compared to the consensus estimate of $4.25 billion. During the same period last year, the firm posted $2.46 EPS. The company’s revenue for the quarter was up 41.0% on a year-over-year basis. On average, research analysts expect that Becton Dickinson and Co will post 11.01 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 28th. Investors of record on Friday, September 7th were given a $0.75 dividend. The ex-dividend date was Thursday, September 6th. This represents a $3.00 annualized dividend and a yield of 1.24%. Becton Dickinson and’s dividend payout ratio is presently 31.65%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Recommended Story: How does inflation affect different investments?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.